Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus LA-06 is a specific probiotic strain of the species *Lactobacillus acidophilus* being investigated as a live biotherapeutic product. It is primarily studied for its potential to modulate the gut-thyroid axis, particularly in patients with newly diagnosed Graves' disease. The strain is hypothesized to influence immune function and gut microbiota composition, which may in turn alleviate psychiatric comorbidities such as anxiety, depression, and insomnia often associated with hyperthyroidism. In clinical research, it is typically evaluated as an adjunctive therapy to standard antithyroid medications like methimazole.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus acidophilus LA-06.